Skip to main content
. 2020 Dec 21;36(1):307–318. doi: 10.1080/14756366.2020.1861606

Figure 5.

Figure 5.

Docking of compounds Vd, Ve and the reference ligand Sorafenib into VEGFR active sites. (a) Compounds Vd. (b) Compound Ve. (c) Sorafenib.